ASCO: GenFleet’s KRAS G12C/EGFR Combo Sets Sail In First-Line NSCLC
IO, Chemo-Free Strategy
Excluding PD-1 inhibitors in its combination strategy for oncology, preliminary results from GenFleet’s Phase II KROCUS study presented at ASCO demonstrate promising efficacy for fulzerasib plus cetuximab in the first-line treatment of KRAS G12C-mutated, advanced non-small cell lung cancer.
